Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Gets Canadian Clearance for Respiratory Virus Panel

NEW YORK (GenomeWeb News) – Luminex said today that Health Canada has cleared for marketing the firm’s xTAG Respiratory Virus Panel, which detects 18 respiratory viruses and subtypes that are responsible for the majority of respiratory viral infections.
 
The panel is based on Luminex’s xMAP multiplex technology and was developed by the firm’s Toronto-based subsidiary, Luminex Molecular Diagnostics.
 
Among the viruses that the xTAG RVP detects are adenovirus, coronavirus, enterovirus, influenza, metapneumovirus, parainfluenza, and respiratory syncytial virus. It also detects subtypes of these viruses.
 
"Because it quickly and simultaneously detects the presence or absence of 18 different virus types and subtypes, xTAG RVP allows physicians to diagnose an infection and make appropriate management decisions,” said James Mahony, director of the Regional Virology Laboratory at St. Joseph's Healthcare, who helped develop the test. “It can detect viruses that cannot be detected with conventional tests and can accurately diagnose patients infected with multiple respiratory viruses."
 
The xTAG RVP is already cleared for marketing in Europe and the US.
 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.